Literature DB >> 1648361

Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines.

D Wrede1, J A Tidy, T Crook, D Lane, K H Vousden.   

Abstract

Mutations within the tumor suppressor genes Rb-1 and p53 are commonly found in many human malignancies, and loss of wild-type function of both p53 and RB appear to be important events in the development of these malignancies. Interference with normal RB and p53 function in the cell has apparently also been exploited by the oncogenic genital human papillomaviruses (HPVs), which encode transforming proteins capable of binding cellular RB and p53 proteins. We have investigated the expression of RB and p53 in a series of eight cervical carcinoma cell lines, six of which contain HPV sequences and two of which have arisen apparently independently of HPV infection. In the six HPV-positive lines, no evidence of abnormal RB or p53 protein could be detected. However, there was evidence for abnormal RB and p53 in the two HPV-negative lines. These data are consistent with the hypothesis that loss of wild-type RB and p53 function is necessary for tumor development and that such loss can occur either by mutation within the cellular gene or by expression of viral proteins capable of complexing wild-type cellular proteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648361     DOI: 10.1002/mc.2940040302

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  23 in total

1.  Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability.

Authors:  M H Kubbutat; K H Vousden
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

2.  URI expression in cervical cancer cells is associated with higher invasion capacity and resistance to cisplatin.

Authors:  Junxia Gu; Yuting Liang; Longwei Qiao; Yaojuan Lu; Xiaoxia Hu; Dongwei Luo; Na Li; Leilei Zhang; Yiyang Chen; Jialu Du; Qiping Zheng
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

3.  Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins.

Authors:  J M Huibregtse; M Scheffner; P M Howley
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

4.  Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600.

Authors:  Kyung-Won Huh; Joseph DeMasi; Hidesato Ogawa; Yoshihiro Nakatani; Peter M Howley; Karl Münger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

5.  Transforming properties of the cottontail rabbit papillomavirus oncoproteins Le6 and SE6 and of the E8 protein.

Authors:  J B Harry; F O Wettstein
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Human papillomavirus type 16 E7 oncoprotein associates with E2F6.

Authors:  Margaret E McLaughlin-Drubin; Kyung-Won Huh; Karl Münger
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

7.  Immunohistochemical detection of p53 protein in cutaneous lesions from transplant recipients harbouring human papillomavirus DNA.

Authors:  I Pélisson; Y Chardonnet; S Euvrard; D Schmitt
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins.

Authors:  M Scheffner; T Takahashi; J M Huibregtse; J D Minna; P M Howley
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

9.  Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.

Authors:  F Hoppe-Seyler; K Butz
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53.

Authors:  J M Huibregtse; M Scheffner; P M Howley
Journal:  Mol Cell Biol       Date:  1993-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.